MAPK8 and renal carcinoma: In conclusion, our systematic investigation revealed the detailed molecular mechanism underlying cordycepin-induced JNK signaling activation through inhibition of c-FLIPL expression, and demonstrates the potential of cordycepin as a therapeutic agent for renal cancer treatment.